Pratts disclose 7.4% stake in NeuroOne Medical (NMTC) after reverse split

Rhea-AI Filing Summary

NeuroOne Medical Technologies Corporation Schedule 13G reports that Brian Pratt and Barbara Pratt each beneficially own 627,344 shares of Common Stock, representing 7.4% of the class. The percentage is computed on 8,420,999 shares outstanding following a 1-for-6 reverse stock split of 50,525,995 shares effective April 15, 2026.

The shares are held in a joint account between each Reporting Person and their spouse; shared voting and dispositive power are reported for each at 627,344 shares. The filing includes a joint filing agreement dated April 21, 2026.

Insights

Beneficial Ownership Analyst

Holders report joint ownership equal to 7.4% post reverse split.

The filing discloses that each Reporting Person holds 627,344 shares with shared voting and dispositive power, and that the ownership percentage is calculated on 8,420,999 shares outstanding after a 1-for-6 reverse split effective April 15, 2026. This clarifies stake size on a post-split basis.

Key dependencies include the stated outstanding share count and the reverse split effectiveness; subsequent filings could change calculated percentages if further corporate actions occur.

Key Figures

Shares beneficially owned (each): 627,344 shares Percent of class: 7.4% Shares outstanding before split: 50,525,995 shares +2 more

5 metrics

Shares beneficially owned (each) 627,344 shares Reported held in a joint account by each Reporting Person

Percent of class 7.4% Calculated on 8,420,999 shares outstanding post reverse split

Shares outstanding before split 50,525,995 shares Outstanding as of February 13, 2026, before 1-for-6 reverse split

Shares outstanding after split 8,420,999 shares Shares outstanding used to compute percentage after 1-for-6 reverse split effective April 15, 2026

Reverse split ratio 1-for-6 Reverse stock split effective April 15, 2026

Key Terms

Schedule 13G, beneficially owned, reverse stock split, shared dispositive power

4 terms

Schedule 13G regulatory

"Schedule 13G reports that Brian Pratt and Barbara Pratt each beneficially own 627,344 shares"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"Amount beneficially owned: The information set forth on the cover page of this is incorporated herein"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

reverse stock split corporate

"1-for-6 reverse stock split of 50,525,995 shares of Common Stock outstanding"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

shared dispositive power regulatory

"Shared Dispositive Power 627,344.00"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

NeuroOne Medical Technologies Corporation

(Name of Issuer)

Common Stock

(Title of Class of Securities)

64130M308

(CUSIP Number)

04/14/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 64130M308

1

Names of Reporting Persons

Brian Pratt

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 627,344.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 627,344.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

627,344.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.4 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 627,344 shares of common stock, par value $0.001 per share ("Common Stock"), of NeuroOne Medical Technologies Corporation (the "Company"), held in a joint account with Brian Pratt's spouse. The percentage in box 11 is based on 8,420,999 shares of Common Stock outstanding following a 1-for-6 reverse stock split of 50,525,995 shares of Common Stock outstanding as of February 13, 2026, as reported in the Company's Quarterly Report on Form 10-Q filed on February 17, 2026. The reverse stock split was effective as of April 15, 2026, as reported in the Company's Current Report on Form 8-K filed on April 14, 2026.

SCHEDULE 13G

CUSIP Number(s): 64130M308

1

Names of Reporting Persons

Barbara Pratt

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 627,344.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 627,344.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

627,344.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.4 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 627,344 shares of common stock, par value $0.001 per share ("Common Stock"), of NeuroOne Medical Technologies Corporation (the "Company"), held in a joint account with Barbara Pratt's spouse. The percentage in box 11 is based on 8,420,999 shares of Common Stock outstanding following a 1-for-6 reverse stock split of 50,525,995 shares of Common Stock outstanding as of February 13, 2026, as reported in the Company's Quarterly Report on Form 10-Q filed on February 17, 2026. The reverse stock split was effective as of April 15, 2026, as reported in the Company's Current Report on Form 8-K filed on April 14, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NeuroOne Medical Technologies Corporation
(b)	Address of issuer's principal executive offices: 7599 Anagram Drive, Eden Prairie, MN 55344
Item 2.
(a)	Name of person filing: Brian Pratt; and Barbara Pratt
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each Reporting Person is 5950 Berkshire Lane, Ste. 800, Dallas, Texas 75225.
(c)	Citizenship: Each Reporting Person is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 64130M308
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
(b)	Percent of class: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information set forth on the cover page of this Schedule 13G is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Brian Pratt

Signature:	/s/ Brian Pratt
Name/Title:	Brian Pratt
Date:	04/21/2026

Barbara Pratt

Signature:	/s/ Barbara Pratt
Name/Title:	Barbara Pratt
Date:	04/21/2026

Exhibit Information

Joint Filing Agreement, dated as of April 21, 2026, by and between the Reporting Persons, attached hereto.

FAQ

What stake does Brian Pratt hold in NeuroOne (NMTC)?

Brian Pratt beneficially owns 627,344 shares, representing 7.4% of the Common Stock based on 8,420,999 shares outstanding after a 1-for-6 reverse split effective April 15, 2026.

Do Brian and Barbara Pratt have voting power over the reported shares?

Each Reporting Person reports shared voting power and shared dispositive power over 627,344 shares, reflecting joint account ownership with their spouse as stated in the filing and joint filing agreement dated April 21, 2026.

How was the 7.4% ownership percentage calculated?

The percentage is based on 8,420,999 shares outstanding after a 1-for-6 reverse stock split of 50,525,995 shares; the reverse split was effective April 15, 2026, per the filing's explanatory comment.

When were the Schedule 13G signatures and joint filing agreement dated?

The Schedule 13G is signed by both Reporting Persons on April 21, 2026, and it references a Joint Filing Agreement dated April 21, 2026 attached as an exhibit to the filing.

Does the filing disclose sole control over the reported shares?

No; the filing reports 0 sole voting power and 0 sole dispositive power for each Reporting Person and lists 627,344 shares as shared voting and dispositive power held in a joint account.